Ontology highlight
ABSTRACT:
SUBMITTER: Jakubowiak AJ
PROVIDER: S-EPMC5162553 | biostudies-literature | 2012 Aug
REPOSITORIES: biostudies-literature
Jakubowiak Andrzej J AJ Dytfeld Dominik D Griffith Kent A KA Lebovic Daniel D Vesole David H DH Jagannath Sundar S Al-Zoubi Ammar A Anderson Tara T Nordgren Brian B Detweiler-Short Kristen K Stockerl-Goldstein Keith K Ahmed Asra A Jobkar Terri T Durecki Diane E DE McDonnell Kathryn K Mietzel Melissa M Couriel Daniel D Kaminski Mark M Vij Ravi R
Blood 20120604 9
This phase 1/2 study in patients with newly diagnosed multiple myeloma (N = 53) assessed CRd--carfilzomib (20, 27, or 36 mg/m2, days 1, 2, 8, 9, 15, 16 and 1, 2, 15, 16 after cycle 8), lenalidomide (25 mg/d, days 1-21), and weekly dexamethasone (40/20 mg cycles 1-4/5+)--in 28-day cycles. After cycle 4, transplantation-eligible candidates underwent stem cell collection (SCC) then continued CRd with the option of transplantation. The maximum planned dose level (carfilzomib 36 mg/m2) was expanded i ...[more]